Infigratinib – Uses, Dosage, Side Effects, Interaction Infigratinib is a FGF receptor kinase inhibitor that is used in the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. Infigratinib is associated with transient and usually mild elevations in serum aminotransferase during therapy, but has not been convincingly linked to cases of clinically apparent liver injury. Infigratinib is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumor growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. On May 28, 2021, the FDA granted accelerated approval to infigratinib – under the market name Truseltiq – for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. This approval follows [pemigatinib], another FGFR inhibitor approved by the FDA for the same therapeutic indication. Infigratinib Phosphate is the phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of angiogenesis and cell proliferation, and the induction of cell death in tumors with activating FGFR amplifications, mutations, or fusions. FGFRs are a family of receptor tyrosine kinases that are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Activating FGFR amplifications, mutations, or fusions occur in various cancer cell types. Infigratinib Mesylate is the mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases that may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Mechanism of Action Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors that play a role in cell proliferation, differentiation, migration, survival, and angiogenesis. Upon binding of extracellular signals, primarily fibroblast growth factors, FGFR dimerizes to promote the phosphorylation of downstream molecules and activation of the Ras-mitogen-activated protein kinase (MAPK) pathway. In some cancers, the FGFR signaling pathway is aberrant and disrupted, leading to unregulated cell proliferation and growth, including malignant cells. Alterations in the FGFR receptors, including mutations, amplifications, and fusions, are associated with a wide array of neoplasms, including prostate, urothelial, ovarian, breast, and liver cancer. In particular, FGFR2 fusion is closely related to intrahepatic cholangiocarcinoma: recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in FGFR2 fusion proteins. Alterations in FGFR in tumors can lead to constitutive FGFR signaling, supporting the proliferation and survival of malignant cells. Infigratinib is a reversible, non-competitive inhibitor of all four FGFR subtypes – FGFR1, FGFR2, FGFR3, and FGFR4 – that blocks FGFR signaling and inhibits cell proliferation in cancer cell lines with activating FGFR amplification, mutations, or fusions. Out of the four FGFR subtypes, infigratinib has the highest affinity for FGFR1, FGFR2, and FGFR3. Infigratinib binds to the allosteric site between the two kinase lobes of the FGFR – or more specifically, to the ATP-binding cleft. Binding to this cleft prevents autophosphorylation of the receptor and blocks downstream signaling cascades that would otherwise activate MAPK. Infigratinib is an anti-tumour agent that works to suppress tumour growth in cholangiocarcinoma. It exhibits anti-tumour activity in mouse and rat xenograft models of human tumours with activating FGFR2 or FGFR3 alterations, such as FGFR2-TTC28 or FGFR2-TRA2B fusions. In clinical trials, patients with cholangiocarcinoma who were treated with infigratinib had an overall response rate of 23% – where one patient had a complete response – and a duration of response of 5.5 months, with a range between 0.03 and 28.3 months. Some patients with cancers with FGFR mutations display intrinsic resistance to infigratinib, leading to negligible therapeutic efficacy: investigations are ongoing to target molecular pathways to combat drug resistance. Indications Infigratinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. Treatment of cholangiocarcinoma Treatment of achondroplasia Infigratinib is an FGF receptor kinase inhibitor that is used in the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. Infigratinib is an FGFR inhibitor used to treat locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) rearrangement. Unresectable, locally advanced Cholangiocarcinomas Unresectable, metastatic Cholangiocarcinomas Use in Cancer Infigratinib phosphate is approved to treat: Cholangiocarcinoma (bile duct cancer) has spread and cannot be removed with surgery. It is used in adults whose cancer has been treated and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene. Infigratinib phosphate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients. Infigratinib phosphate is also being studied in the treatment of other types of cancer. Contraindications high amount of phosphate in the blood liver problems pregnancy a patient who is producing milk and breastfeeding chronic kidney disease stage 3B (moderate) chronic kidney disease stage 4 (severe) kidney disease with likely reduction in kidney function detachment of retinal pigment epithelium Child-Pugh class A liver impairment Child-Pugh class B liver impairment Dosage Strengths: 125 mg daily dose; 100 mg daily dose; 75 mg daily dose; 50 mg daily dose. Cholangiocarcinoma of biliary tract 125 mg (one 100 mg capsule and one 25 mg capsule) orally once a day for 21 days on 7 days off of a 28-day cycle Continue treatment until disease progression or unacceptable toxicity. Select patients for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma based on the presence of an FGFR2 fusion or rearrangement. Information on FDA-approved test(s) for the detection of FGFR2 fusions or rearrangements in cholangiocarcinoma is available at: http://www.fda.gov/CompanionDiagnostics. Renal Dose Adjustments Mild or moderate renal dysfunction (CrCl 30 to 89 mL/min): 100 mg orally once a day for 21 days on 7 days off of a 28-day cycle Severe renal dysfunction (CrCl 15 to less than 30 mL/min): Data not available Liver Dose Adjustments Mild liver dysfunction (total bilirubin greater than the upper limit of normal [ULN] to 1.5 × ULN or AST greater than ULN ): 100 mg orally once a day for 21 days on 7 days off of a 28-day cycle Moderate liver dysfunction (total bilirubin greater than 1.5 to 3 × ULN with any AST): 75 mg orally once a day for 21 days on 7 days off of a 28-day cycle Severe liver dysfunction (total bilirubin greater than 3 × ULN with any AST): Not established Dose Adjustments Dose Reduction for Adverse Reactions: First dose reduction: 100 orally once a day Second dose reduction: 75 mg orally once a day Third dose reduction: 50 mg orally once a day Dose Modification for Adverse Reactions: Retinal Pigment Epithelial Detachment (RPED): Continue treatment at the current dose and continue periodic ophthalmic evaluation. If resolved within 14 days, continue treatment at the current dose. If unresolved within 14 days, withhold treatment until resolved; then resume at previous dose or at a lower dose. Hyperphosphatemia: If serum phosphate greater than 5.5 to 7.5 or less mg/dL: Continue treatment at the current dose and start or adjust the phosphate binder dose according to clinical practice. Monitor serum phosphate weekly. Phosphate binder dosing should be held during the week off therapy each cycle (Days 22-28) and during dose interruptions for non-hyperphosphatemia adverse events. If serum phosphate greater than 7.5 mg/dL or single phosphate greater than 9 mg/dL independent of duration of dose of the phosphate lowering therapy: Withhold treatment until level returns to serum phosphate of 5.5 mg/dL or less. If serum phosphate greater than 7.5 mg/dL occurred for less than 7 days: Restart treatment at the same dose with maximal phosphate binder dosing. If serum phosphate greater than 7.5 mg/dL for greater than 7 days or if patient had a one-time serum phosphate of greater than 9 mg/dL: Resume treatment at the next lower dose level with maximal phosphate binder dosing. Serum phosphate with life-threatening consequences; urgent intervention indicated (e.g., dialysis): Permanently discontinue treatment. Other Adverse Reactions: Grade 3: Withhold dose until resolved to Grade 1 or less, then resume at the next lower dose level. If not resolved within 14 days or less, permanently discontinue treatment. Grade 4: Permanently discontinue treatment. Dosage Modification for Concomitant Use of Gastric Acid Reducing Agents: It is recommended to avoid the coadministration of a proton pump inhibitor (PPI), a histamine-2 (H2) receptor antagonist, or a locally-acting antacid. If H2-antagonist coadministration cannot be avoided it is recommended to separate the administration of this drug by 2 hours before or 10 hours after. If locally-acting antacid coadministration cannot be avoided it is recommended to separate the administration of this drug by 2 hours before or 2 hours after. Administration advice: Take on an empty stomach at least 1 hour before or 2 hours after food. Swallow capsules whole with water. Do not crush, chew, or dissolve capsules. Advise the patient to read the FDA-approved patient labeling (Patient Information). Advise lactating women not to breastfeed during therapy and for at least 1 month after the last dose. Advise females of reproductive potential to use effective contraception during treatment with and for at least 1 month after the last dose. Advise males that are partnered with females of reproductive potential to use effective contraception during treatment with and for at least 1 month after the last dose. Advise patients that if a dose is missed and it has passed 4 hours or more or if vomiting, skip the dose and take the next scheduled dose at its regular time. Advise patients that this drug may cause nail disorders. Advise patients that this drug may cause ocular toxicity and to immediately inform their healthcare provider if they experience any visual changes. Advise patients to use artificial tear substitutes or hydrating or lubricating eye gels to prevent or treat dry eyes. Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products. Advise patients that this drug may cause hyperphosphatemia and soft tissue mineralization and to immediately inform their healthcare provider of any symptoms related to acute changes in phosphate levels such as muscle cramps, numbness, or tingling around the mouth. Advise patients to avoid grapefruit products during treatment. Side Effects The Most Common diarrhea nausea vomiting constipation loss of appetite changes in taste heartburn or indigestion stomach pain sores on the lips, mouth, or throat dry mouth and/or skin nail disorders hair loss headache fatigue swelling of hands, feet, legs or ankles pain in joints, arms, or legs nose bleeds blurred vision, floaters in the eye, seeing flashes of light, or other changes in vision muscle cramps, numbness, or tingling around the mouth fever, chills, or other signs of infection blistering and peeling skin More common Blindness blurred vision confusion constipation decreased vision depression difficulty in breathing dry eye dry mouth eyelash changes headache incoherent speech increased urination irregular heartbeats loss of appetite metallic taste mood or mental changes muscle cramps in the hands, arms, feet, legs, or face muscle weakness nausea numbness and tingling around the mouth, fingertips, or feet redness, swelling, or itching of the eyelid redness, swelling, pain, or ulceration of the skin scaling of the skin on the hands and feet seizures stomach cramps thirst tingling of the hands and feet tremor unusual tiredness vomiting weight loss Rare Chills cough or hoarseness dizziness, lightheadedness, or fainting dry mouth fast heartbeat fever or chills lower back or side pain painful or difficult urination rapid, shallow breathing Acid or sour stomach belching bloody nose change in taste decreased weight diarrhea difficulty in moving dry skin hair loss, thinning of hair heartburn indigestion lack or loss strength loss of taste muscle pain or stiffness pain in the arms or legs pain in the joints redness or soreness around the fingernails or loosening of the fingernails stomach discomfort, upset, or pain swelling of the hands, ankles, feet, or lower legs swelling or inflammation of the mouth Drug Interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Infigratinib. Abametapir The serum concentration of Infigratinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Infigratinib can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Infigratinib. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Infigratinib. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Infigratinib. Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Infigratinib. Acetazolamide The metabolism of Infigratinib can be decreased when combined with Acetazolamide. Adalimumab The metabolism of Infigratinib can be increased when combined with Adalimumab. Albendazole The metabolism of Infigratinib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Infigratinib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Infigratinib. Almasilate The serum concentration of Infigratinib can be decreased when it is combined with Almasilate. Alpelisib The metabolism of Alpelisib can be decreased when combined with Infigratinib. Aluminium The serum concentration of Infigratinib can be decreased when it is combined with Aluminium. Aluminium phosphate The serum concentration of Infigratinib can be decreased when it is combined with Aluminium phosphate. Aluminum hydroxide The serum concentration of Infigratinib can be decreased when it is combined with Aluminum hydroxide. Aminoglutethimide The metabolism of Infigratinib can be increased when combined with Aminoglutethimide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Infigratinib. Amiodarone The metabolism of Infigratinib can be decreased when combined with Amiodarone. Amobarbital The metabolism of Infigratinib can be increased when combined with Amobarbital. Amprenavir The metabolism of Infigratinib can be decreased when combined with Amprenavir. Anakinra The metabolism of Infigratinib can be increased when combined with Anakinra. Apalutamide The metabolism of Infigratinib can be increased when combined with Apalutamide. Apremilast The metabolism of Infigratinib can be increased when combined with Apremilast. Aprepitant The metabolism of Infigratinib can be decreased when combined with Aprepitant. Armodafinil The metabolism of Infigratinib can be increased when combined with Armodafinil. Articaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Articaine. Asciminib The metabolism of Infigratinib can be decreased when combined with Asciminib. Astemizole The metabolism of Astemizole can be decreased when combined with Infigratinib. Asunaprevir The metabolism of Infigratinib can be increased when combined with Asunaprevir. Atazanavir The metabolism of Infigratinib can be decreased when combined with Atazanavir. Avacopan The metabolism of Infigratinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Infigratinib. Axitinib The metabolism of Axitinib can be decreased when combined with Infigratinib. Azithromycin The metabolism of Infigratinib can be decreased when combined with Azithromycin. Beclomethasone The metabolism of Infigratinib can be increased when combined with Beclomethasone dipropionate. Benzocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Benzyl alcohol. Berotralstat The metabolism of Infigratinib can be decreased when combined with Berotralstat. Betamethasone The metabolism of Infigratinib can be increased when combined with Betamethasone. Betamethasone pho The metabolism of Infigratinib can be increased when combined with Betamethasone phosphate. Bexarotene The metabolism of Infigratinib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Infigratinib. Bifonazole The metabolism of Infigratinib can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Infigratinib can be increased when combined with Bimekizumab. Bismuth subnitrate The serum concentration of Infigratinib can be decreased when it is combined with Bismuth subnitrate. Boceprevir The metabolism of Infigratinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Infigratinib. Bosentan The metabolism of Infigratinib can be increased when combined with Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Infigratinib. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Infigratinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Infigratinib. Budesonide The metabolism of Infigratinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Bupivacaine. Buprenorphine The metabolism of Infigratinib can be decreased when combined with Buprenorphine. Busulfan The metabolism of Busulfan can be decreased when combined with Infigratinib. Butacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Butacaine. Butalbital The metabolism of Infigratinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Infigratinib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Infigratinib. Calcitriol The metabolism of Infigratinib can be increased when combined with Calcitriol. Calcium carbonate The serum concentration of Infigratinib can be decreased when it is combined with Calcium carbonate. Canakinumab The metabolism of Infigratinib can be increased when combined with Canakinumab. Candicidin The metabolism of Infigratinib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Infigratinib can be decreased when combined with Cannabidiol. Capsaicin The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Capsaicin. Carbamazepine The metabolism of Infigratinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Infigratinib. Cefradine The metabolism of Infigratinib can be increased when combined with Cefradine. Cenobamate The serum concentration of Infigratinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Infigratinib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Ceritinib can be decreased when combined with Infigratinib. Cerivastatin The metabolism of Infigratinib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Infigratinib can be increased when combined with Certolizumab pegol. Chloramphenicol The metabolism of Infigratinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Chloroprocaine. Chlorpromazine The metabolism of Infigratinib can be increased when combined with Chlorpromazine. Cimetidine The serum concentration of Infigratinib can be decreased when it is combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Cinchocaine. Ciprofloxacin The metabolism of Infigratinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Infigratinib can be decreased when combined with Cisapride. Citalopram The metabolism of Infigratinib can be decreased when combined with Citalopram. Clarithromycin The metabolism of Infigratinib can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Infigratinib can be increased when combined with Clevidipine. Clobazam The metabolism of Infigratinib can be increased when combined with Clobazam. Clobetasol propio The metabolism of Infigratinib can be increased when combined with Clobetasol propionate. Clofazimine The metabolism of Infigratinib can be decreased when combined with Clofazimine. Clofibrate The metabolism of Infigratinib can be increased when combined with Clofibrate. Clomipramine The metabolism of Clomipramine can be decreased when combined with Infigratinib. Clonidine The metabolism of Clonidine can be decreased when combined with Infigratinib. Clozapine The metabolism of Infigratinib can be decreased when combined with Clozapine. Cobicistat The metabolism of Infigratinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Infigratinib. Cocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Cocaine. Conivaptan The metabolism of Infigratinib can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Infigratinib. Corticotropin The metabolism of Infigratinib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Infigratinib can be increased when combined with Cortisone acetate. You Might Also Read How Can I Treat For Facial Wrinkles With Botulinum Toxin Crizotinib The metabolism of Infigratinib can be decreased when combined with Crizotinib. Curcumin The metabolism of Infigratinib can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Infigratinib. Cyclosporine The metabolism of Infigratinib can be decreased when combined with Cyclosporine. Cyproterone acetate The metabolism of Infigratinib can be decreased when combined with Cyproterone acetate. Dabrafenib The serum concentration of Infigratinib can be decreased when it is combined with Dabrafenib. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Infigratinib. Dalfopristin The metabolism of Infigratinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Infigratinib can be decreased when combined with Danazol. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Infigratinib. Darunavir The metabolism of Infigratinib can be decreased when combined with Darunavir. Dasatinib The metabolism of Dasatinib can be decreased when combined with Infigratinib. Daunorubicin The metabolism of Infigratinib can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Infigratinib can be increased when combined with Deferasirox. Deflazacort The metabolism of Infigratinib can be increased when combined with Deflazacort. Delavirdine The metabolism of Infigratinib can be decreased when combined with Delavirdine. Desipramine The metabolism of Infigratinib can be decreased when combined with Desipramine. Desvenlafaxine The metabolism of Infigratinib can be decreased when combined with Desvenlafaxine. Dexamethasone The metabolism of Infigratinib can be increased when combined with Dexamethasone. Dexamethasone The metabolism of Infigratinib can be increased when combined with Dexamethasone acetate. Dexlansoprazole The serum concentration of Infigratinib can be decreased when it is combined with Dexlansoprazole. Dextropropoxyphene The metabolism of Infigratinib can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Infigratinib can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Infigratinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Infigratinib can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Infigratinib. Dihydroergocornine The metabolism of Infigratinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Infigratinib. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Infigratinib. Diltiazem The metabolism of Infigratinib can be decreased when combined with Diltiazem. Dimethyl sulfoxide The metabolism of Infigratinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The metabolism of Infigratinib can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Diphenhydramine. Docetaxel The metabolism of Docetaxel can be decreased when combined with Infigratinib. Dofetilide The metabolism of Dofetilide can be decreased when combined with Infigratinib. Doxazosin The metabolism of Infigratinib can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Infigratinib. Dronedarone The metabolism of Infigratinib can be decreased when combined with Dronedarone. Drospirenone The metabolism of Infigratinib can be decreased when combined with Drospirenone. Duvelisib The metabolism of Duvelisib can be decreased when combined with Infigratinib. Dyclonine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Dyclonine. Ebastine The metabolism of Infigratinib can be decreased when combined with Ebastine. Echinacea The metabolism of Infigratinib can be increased when combined with Echinacea. Econazole The metabolism of Infigratinib can be decreased when combined with Econazole. Efavirenz The metabolism of Infigratinib can be decreased when combined with Efavirenz. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Infigratinib. Elvitegravir The metabolism of Infigratinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Infigratinib can be increased when combined with Emapalumab. Enasidenib The metabolism of Enasidenib can be decreased when combined with Infigratinib. Entrectinib The metabolism of Entrectinib can be decreased when combined with Infigratinib. Enzalutamide The metabolism of Infigratinib can be increased when combined with Enzalutamide. Epinephrine The metabolism of Infigratinib can be decreased when combined with Epinephrine. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Infigratinib. Ergotamine The metabolism of Infigratinib can be decreased when combined with Ergotamine. Erlotinib The metabolism of Erlotinib can be decreased when combined with Infigratinib. Erythromycin The metabolism of Infigratinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Infigratinib. Esketamine The metabolism of Infigratinib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Infigratinib can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Infigratinib can be increased when combined with Eslicarbazepine acetate. Esomeprazole The serum concentration of Infigratinib can be decreased when it is combined with Esomeprazole. Estetrol The metabolism of Estetrol can be decreased when combined with Infigratinib. Estradiol acetate The metabolism of Infigratinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Infigratinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Infigratinib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Infigratinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Infigratinib can be increased when combined with Estradiol valerate. Etanercept The metabolism of Infigratinib can be increased when combined with Etanercept. Ethambutol The metabolism of Infigratinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Infigratinib can be increased when combined with Ethanol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Infigratinib. Etoricoxib The metabolism of Infigratinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Infigratinib can be increased when combined with Etravirine. Everolimus The metabolism of Everolimus can be decreased when combined with Infigratinib. Famotidine The serum concentration of Infigratinib can be decreased when it is combined with Famotidine. Felbamate The metabolism of Infigratinib can be increased when combined with Felbamate. Fenofibrate The metabolism of Infigratinib can be decreased when combined with Fenofibrate. Fexinidazole The metabolism of Infigratinib can be decreased when combined with Fexinidazole. Flucloxacillin The metabolism of Infigratinib can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Infigratinib can be decreased when combined with Fluconazole. Flunisolide The metabolism of Infigratinib can be increased when combined with Flunisolide. Fluocinolone The metabolism of Infigratinib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Infigratinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Infigratinib can be increased when combined with Fluocortolone. Fluoxetine The metabolism of Infigratinib can be decreased when combined with Fluoxetine. Fluticasone The metabolism of Infigratinib can be increased when combined with Fluticasone. Fluticasone pro The metabolism of Infigratinib can be decreased when combined with Fluticasone propionate. Fluvoxamine The metabolism of Infigratinib can be decreased when combined with Fluvoxamine. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Infigratinib. Formestane The metabolism of Infigratinib can be increased when combined with Formestane. Fosamprenavir The metabolism of Infigratinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Infigratinib can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Infigratinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Infigratinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Infigratinib can be decreased when combined with Fostamatinib. Fusidic acid The metabolism of Infigratinib can be decreased when combined with Fusidic acid. Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Infigratinib. Ginkgo biloba The metabolism of Infigratinib can be decreased when combined with Ginkgo biloba. You Might Also Read Etanercept; Uses, Dosage, Side Effects, Drug Interactions Glecaprevir The metabolism of Infigratinib can be decreased when combined with Glecaprevir. Glyburide The metabolism of Infigratinib can be decreased when combined with Glyburide. Glycerol pheny The metabolism of Infigratinib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Infigratinib can be increased when combined with Golimumab. Griseofulvin The metabolism of Infigratinib can be increased when combined with Griseofulvin. Haloperidol The metabolism of Infigratinib can be decreased when combined with Haloperidol. Hydralazine The metabolism of Infigratinib can be decreased when combined with Hydralazine. Hydrocortamate The metabolism of Infigratinib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Infigratinib can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Infigratinib can be increased when combined with Hydrocortisone acetate. Hydrocortisone but The metabolism of Infigratinib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone succ The metabolism of Infigratinib can be increased when combined with Hydrocortisone succinate. Hydrotalcite The serum concentration of Infigratinib can be decreased when it is combined with Hydrotalcite. Idelalisib The metabolism of Idelalisib can be decreased when combined with Infigratinib. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Infigratinib. Imatinib The metabolism of Infigratinib can be decreased when combined with Imatinib. Indinavir The metabolism of Infigratinib can be decreased when combined with Indinavir. Infliximab The metabolism of Infigratinib can be increased when combined with Infliximab. Irbesartan The metabolism of Infigratinib can be decreased when combined with Irbesartan. Irinotecan The metabolism of Irinotecan can be decreased when combined with Infigratinib. Isavuconazole The metabolism of Infigratinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Infigratinib can be decreased when combined with Isavuconazonium. Isoniazid The metabolism of Infigratinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Infigratinib can be decreased when combined with Isradipine. Itraconazole The metabolism of Infigratinib can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Infigratinib can be decreased when combined with Ivacaftor. Ivosidenib The metabolism of Infigratinib can be increased when combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Infigratinib. Ixazomib The metabolism of Ixazomib can be decreased when combined with Infigratinib. Ketazolam The metabolism of Infigratinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Infigratinib can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Infigratinib can be decreased when combined with Lacosamide. Lanreotide The metabolism of Infigratinib can be decreased when combined with Lanreotide. Lansoprazole The serum concentration of Infigratinib can be decreased when it is combined with Lansoprazole. Lapatinib The metabolism of Infigratinib can be decreased when combined with Lapatinib. Lefamulin The metabolism of Lefamulin can be decreased when combined with Infigratinib. Lesinurad The metabolism of Infigratinib can be increased when combined with Lesinurad. Letermovir The metabolism of Infigratinib can be decreased when combined with Letermovir. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Infigratinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Levobupivacaine. Levoketoconazole The metabolism of Infigratinib can be decreased when combined with Levoketoconazole. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Infigratinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Lidocaine. Linagliptin The metabolism of Infigratinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Infigratinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Infigratinib. Lomitapide The metabolism of Lomitapide can be decreased when combined with Infigratinib. Lonafarnib The metabolism of Infigratinib can be decreased when combined with Lonafarnib. Lopinavir The metabolism of Infigratinib can be decreased when combined with Lopinavir. Lorlatinib The metabolism of Infigratinib can be increased when combined with Lorlatinib. Losartan The metabolism of Infigratinib can be decreased when combined with Losartan. Lovastatin The metabolism of Infigratinib can be decreased when combined with Lovastatin. Luliconazole The metabolism of Infigratinib can be decreased when combined with Luliconazole. Lumacaftor The metabolism of Infigratinib can be increased when combined with Lumacaftor. Magaldrate The serum concentration of Infigratinib can be decreased when it is combined with Magaldrate. Magnesium carbonate The serum concentration of Infigratinib can be decreased when it is combined with Magnesium carbonate. Magnesium hydroxide The serum concentration of Infigratinib can be decreased when it is combined with Magnesium hydroxide. Magnesium oxide The serum concentration of Infigratinib can be decreased when it is combined with Magnesium oxide. Magnesium silicate The serum concentration of Infigratinib can be decreased when it is combined with Magnesium silicate. Magnesium trisilicate The serum concentration of Infigratinib can be decreased when it is combined with Magnesium trisilicate. Manidipine The metabolism of Infigratinib can be decreased when combined with Manidipine. Mavacamten The serum concentration of Infigratinib can be decreased when it is combined with Mavacamten. Medroxyprogesterone The metabolism of Infigratinib can be increased when combined with Medroxyprogesterone acetate. Meloxicam The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Meloxicam. Meperidine The metabolism of Infigratinib can be decreased when combined with Meperidine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Mepivacaine. Meprednisone The metabolism of Infigratinib can be increased when combined with Meprednisone. Methadone The metabolism of Infigratinib can be decreased when combined with Methadone. Methantheline The serum concentration of Infigratinib can be decreased when it is combined with Methantheline. Methimazole The metabolism of Infigratinib can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Infigratinib. Methoxy poly The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Infigratinib. Methylene blue The metabolism of Infigratinib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Infigratinib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Infigratinib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Infigratinib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Infigratinib. Methysergide The metabolism of Infigratinib can be decreased when combined with Methysergide. Metreleptin The metabolism of Infigratinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Infigratinib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Infigratinib can be increased when combined with Metyrapone. Miconazole The metabolism of Infigratinib can be decreased when combined with Miconazole. Midazolam The metabolism of Infigratinib can be decreased when combined with Midazolam. Midostaurin The metabolism of Infigratinib can be decreased when combined with Midostaurin. Mifepristone The metabolism of Infigratinib can be increased when combined with Mifepristone. Milnacipran The metabolism of Infigratinib can be decreased when combined with Milnacipran. Miocamycin The metabolism of Infigratinib can be decreased when combined with Miocamycin. Mirtazapine The metabolism of Infigratinib can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Infigratinib can be increased when combined with Mitapivat. Mitotane The metabolism of Infigratinib can be increased when combined with Mitotane. Modafinil The metabolism of Infigratinib can be increased when combined with Modafinil. Mometasone The metabolism of Infigratinib can be increased when combined with Mometasone furoate. Nafcillin The metabolism of Infigratinib can be increased when combined with Nafcillin. Nefazodone The metabolism of Infigratinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Infigratinib can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Infigratinib. Netupitant The metabolism of Infigratinib can be decreased when combined with Netupitant. Niacin The metabolism of Infigratinib can be decreased when combined with Niacin. Nicardipine The metabolism of Infigratinib can be decreased when combined with Nicardipine. Nilotinib The metabolism of Infigratinib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Infigratinib can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Infigratinib can be decreased when combined with Nintedanib. Nizatidine The serum concentration of Infigratinib can be decreased when it is combined with Nizatidine. Norethisterone The metabolism of Infigratinib can be decreased when combined with Norethisterone. Norgestimate The metabolism of Infigratinib can be increased when combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Infigratinib. Noscapine The metabolism of Infigratinib can be decreased when combined with Noscapine. Octreotide The metabolism of Infigratinib can be decreased when combined with Octreotide. Olaparib The metabolism of Olaparib can be decreased when combined with Infigratinib. Omeprazole The serum concentration of Infigratinib can be decreased when it is combined with Omeprazole. Oritavancin The metabolism of Infigratinib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Infigratinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Infigratinib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Infigratinib. Oxcarbazepine The metabolism of Infigratinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Infigratinib can be decreased when combined with Oxybutynin. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Infigratinib. Pacritinib The metabolism of Infigratinib can be decreased when combined with Pacritinib. Palbociclib The metabolism of Palbociclib can be decreased when combined with Infigratinib. Panobinostat The metabolism of Panobinostat can be decreased when combined with Infigratinib. Pantoprazole The serum concentration of Infigratinib can be decreased when it is combined with Pantoprazole. Parathyroid hor The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Infigratinib. Pasireotide The metabolism of Infigratinib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Pazopanib can be decreased when combined with Infigratinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Infigratinib. Pentobarbital The metabolism of Infigratinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Infigratinib can be increased when combined with Perampanel. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Infigratinib. Phenobarbital The metabolism of Infigratinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Infigratinib. Phenylbutazone The metabolism of Infigratinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Infigratinib can be increased when combined with Phenytoin. Pimavanserin The metabolism of Infigratinib can be decreased when combined with Pimavanserin. Pimozide The metabolism of Pimozide can be decreased when combined with Infigratinib. Piperaquine The metabolism of Infigratinib can be decreased when combined with Piperaquine. Pitolisant The serum concentration of Infigratinib can be decreased when it is combined with Pitolisant. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Infigratinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Infigratinib. Posaconazole The metabolism of Infigratinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Infigratinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Infigratinib. Pralsetinib The metabolism of Infigratinib can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Pramocaine. Prednisolone The metabolism of Infigratinib can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Infigratinib can be increased when combined with Prednisolone acetate. Prednisolone phosp The metabolism of Infigratinib can be increased when combined with Prednisolone phosphate. Prednisone acetate The metabolism of Infigratinib can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Infigratinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Prilocaine. Primaquine The metabolism of Infigratinib can be decreased when combined with Primaquine. Primidone The metabolism of Infigratinib can be increased when combined with Primidone. Probenecid The metabolism of Infigratinib can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Proparacaine. Propofol The metabolism of Infigratinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Propoxycaine. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Infigratinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Infigratinib. Quinidine The metabolism of Quinidine can be decreased when combined with Infigratinib. Quinine The metabolism of Infigratinib can be increased when combined with Quinine. Quinupristin The metabolism of Infigratinib can be decreased when combined with Quinupristin. Rabeprazole The serum concentration of Infigratinib can be decreased when it is combined with Rabeprazole. Raloxifene The metabolism of Infigratinib can be decreased when combined with Raloxifene. Ranitidine The serum concentration of Infigratinib can be decreased when it is combined with Ranitidine. Ranolazine The metabolism of Infigratinib can be decreased when combined with Ranolazine. Regorafenib The metabolism of Regorafenib can be decreased when combined with Infigratinib. Remdesivir The metabolism of Infigratinib can be decreased when combined with Remdesivir. Ribociclib The metabolism of Infigratinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Infigratinib can be increased when combined with Rifabutin. Rifampicin The metabolism of Infigratinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Infigratinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Infigratinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Infigratinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Infigratinib can be decreased when combined with Rilpivirine. Rimexolone The metabolism of Infigratinib can be increased when combined with Rimexolone. Ritonavir The metabolism of Infigratinib can be decreased when combined with Ritonavir. Rofecoxib The metabolism of Infigratinib can be increased when combined with Rofecoxib. Roflumilast The metabolism of Infigratinib can be decreased when combined with Roflumilast. Romidepsin The metabolism of Romidepsin can be decreased when combined with Infigratinib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Ropivacaine. Rosuvastatin The metabolism of Infigratinib can be decreased when combined with Rosuvastatin. Roxithromycin The metabolism of Infigratinib can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Infigratinib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Infigratinib can be increased when combined with Rufinamide. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Infigratinib. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Infigratinib. Saquinavir The metabolism of Infigratinib can be decreased when combined with Saquinavir. Sarilumab The metabolism of Infigratinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Infigratinib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Infigratinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Infigratinib can be increased when combined with Secukinumab. Siltuximab The metabolism of Infigratinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Infigratinib can be decreased when combined with Simeprevir. Siponimod The metabolism of Siponimod can be decreased when combined with Infigratinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Infigratinib. Sitaxentan The metabolism of Infigratinib can be decreased when combined with Sitaxentan. Sodium bicarb The serum concentration of Infigratinib can be decreased when it is combined with Sodium bicarbonate. You Might Also Read Citalopram; Uses, Dosage, Side Effects, Interactions, Pregnancy Sodium zirconium The serum concentration of Infigratinib can be decreased when it is combined with Sodium zirconium cyclosilicate. Somatostatin The metabolism of Infigratinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Infigratinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Infigratinib. Sorafenib The metabolism of Sorafenib can be decreased when combined with Infigratinib. Sotorasib The serum concentration of Infigratinib can be decreased when it is combined with Sotorasib. St. John’s Wort The metabolism of Infigratinib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Infigratinib can be decreased when combined with Stiripentol. Sulfamethoxazole The metabolism of Infigratinib can be decreased when combined with Sulfamethoxazole. Sulfinpyrazone The metabolism of Infigratinib can be increased when combined with Sulfinpyrazone. Sunitinib The metabolism of Sunitinib can be decreased when combined with Infigratinib. Suvorexant The metabolism of Infigratinib can be decreased when combined with Suvorexant. Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Infigratinib. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Infigratinib. Tasimelteon The metabolism of Infigratinib can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Infigratinib. Tecovirimat The metabolism of Infigratinib can be increased when combined with Tecovirimat. Telaprevir The metabolism of Infigratinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Infigratinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Infigratinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Infigratinib. Teniposide The metabolism of Teniposide can be decreased when combined with Infigratinib. Tenofovir alafe The metabolism of Infigratinib can be decreased when combined with Tenofovir alafenamide. Terbinafine The metabolism of Infigratinib can be increased when combined with Terbinafine. Terfenadine The metabolism of Infigratinib can be decreased when combined with Terfenadine. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Infigratinib. Testosterone The metabolism of Infigratinib can be increased when combined with Testosterone. Tetracaine The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Tetracaine. Tetracycline The metabolism of Infigratinib can be decreased when combined with Tetracycline. Theophylline The metabolism of Theophylline can be decreased when combined with Infigratinib. Thiamylal The metabolism of Infigratinib can be increased when combined with Thiamylal. Thiotepa The metabolism of Thiotepa can be decreased when combined with Infigratinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Infigratinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Infigratinib. Ticagrelor The metabolism of Infigratinib can be decreased when combined with Ticagrelor. Tioconazole The metabolism of Infigratinib can be decreased when combined with Tioconazole. Tipranavir The metabolism of Infigratinib can be decreased when combined with Tipranavir. Tocilizumab The metabolism of Infigratinib can be increased when combined with Tocilizumab. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Infigratinib. Topiramate The metabolism of Infigratinib can be increased when combined with Topiramate. Trabectedin The metabolism of Trabectedin can be decreased when combined with Infigratinib. Trastuzumab emta The metabolism of Trastuzumab emtansine can be decreased when combined with Infigratinib. Triamcinolone The metabolism of Infigratinib can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Infigratinib can be decreased when combined with Triclabendazole. Troglitazone The metabolism of Infigratinib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Infigratinib can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Infigratinib. Valproic acid The metabolism of Infigratinib can be decreased when combined with Valproic acid. Vandetanib The metabolism of Vandetanib can be decreased when combined with Infigratinib. Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Infigratinib. Venetoclax The metabolism of Infigratinib can be decreased when combined with Venetoclax. Verapamil The metabolism of Infigratinib can be decreased when combined with Verapamil. Viloxazine The metabolism of Infigratinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Vinblastine can be decreased when combined with Infigratinib. Vincristine The metabolism of Vincristine can be decreased when combined with Infigratinib. Vindesine The metabolism of Vindesine can be decreased when combined with Infigratinib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Infigratinib. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Infigratinib. Vitamin E The metabolism of Infigratinib can be increased when combined with Vitamin E. Vonoprazan The serum concentration of Infigratinib can be decreased when it is combined with Vonoprazan. Vorapaxar The metabolism of Infigratinib can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Infigratinib can be decreased when combined with Voriconazole. Warfarin The metabolism of Warfarin can be decreased when combined with Infigratinib. Zafirlukast The metabolism of Infigratinib can be decreased when combined with Zafirlukast. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Infigratinib. Zimelidine The metabolism of Infigratinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Infigratinib can be decreased when combined with Ziprasidone. Zuclopenthixol The metabolism of Infigratinib can be decreased when combined with Zuclopenthixol. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings in animal studies and its mechanism of action TRUSELTIQ can cause fetal harm or loss of pregnancy when administered to a pregnant woman [see Clinical Pharmacology (13.1)]. There are no available data on the use of TRUSELTIQ during pregnancy. Oral administration of infigratinib to pregnant animals during the period of organogenesis at maternal exposures below the human exposure at the clinical dose of 125 mg resulted in malformations, fetal growth retardation, and embryo-fetal death (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of infigratinib or its metabolites in human milk, or their effects on either the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children from TRUSELTIQ, advise women not to breastfeed during treatment and for 1 month after the final dose. How should this medicine be used? Infigratinib comes as a capsule to take by mouth. It is usually taken once daily on an empty stomach (at least 1 hour before or at least 2 hours after food) for the first 21 days of a 28-day cycle. The cycle may be repeated as recommended by your doctor. Take infigratinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take infigratinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the capsules whole with a glass of water; do not split, chew, dissolve, or open them. If you vomit after taking infigratinib, do not take another dose. Continue your regular dosing schedule. Your doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with infigratinib. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before taking infigratinib, tell your doctor and pharmacist if you are allergic to infigratinib, any other medications, or any of the ingredients in infigratinib capsules. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: itraconazole (Sporanox, Tolsura); proton-pump inhibitors, such as lansoprazole (Prevacid), omeprazole (Prilosec), and pantoprazole (Protonix); and rifampin (Rifadin, Rimactane, in Rifamate). Many other medications may also interact with infigratinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. if you are taking antacids, such as aluminum hydroxide/magnesium hydroxide (Maalox), calcium carbonate (Tums), or calcium carbonate and magnesium (Rolaids), take infigratinib 2 hours before or 2 hours after you take the antacid. If you are taking H2 blockers, such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac), take infigratinib 2 hours before or 10 hours after you take the H2 blocker. tell your doctor if you have vision or eye problems or if you have or ever had liver or kidney problems. tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 1 month after your final dose. If you are a male, you and your partner should use birth control during your treatment and for 1 month after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking infigratinib, call your doctor immediately. Infigratinib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed while you are taking infigratinib and for 1 month after your final dose. you should know that this medication may cause dry eyes. Your doctor may tell you to use artificial tears or lubricant eye drops during your treatment with infigratinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214622Orig1s000MultidisciplineR.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214622Orig1s000ltr.pdf https://www.cancer.gov/about-cancer/treatment/drugs/infigratinibphosphate https://pubchem.ncbi.nlm.nih.gov/compound/Infigratinib https://pubchem.ncbi.nlm.nih.gov/compound/Infigratinib-phosphate https://go.drugbank.com/drugs/DB11886 https://www.drugs.com/mtm/infigratinib.html https://en.wikipedia.org/wiki/Infigratinib https://medlineplus.gov/druginfo/meds/a621041.html https://www.mayoclinic.org/drugs-supplements/infigratinib-oral-route/side-effects/drg-20516715 https://www.webmd.com/drugs/2/drug-181583/infigratinib-oral/details/list-contraindications ChEBI http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63451 http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology DrugBank https://www.drugbank.ca/legal/terms_of_use https://www.drugbank.ca/drugs/DB11886 LiverTox https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/books/n/livertox/Infigratinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C88302 https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1852688/ https://www.ebi.ac.uk/chembl/g/#browse/targets Chemical Probes Portal https://www.chemicalprobes.org/bgj-398 Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=C568950 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/INFIGRATINIB IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877 https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) http://idrblab.net/ttd/data/drug/details/D03LWG ChemIDplus https://www.nlm.nih.gov/copyright.html https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0872511347 https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus EPA DSSTox https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources https://comptox.epa.gov/dashboard/DTXSID70236238 https://comptox.epa.gov/dashboard/chemical-lists/ FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A4055ME1VK ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002594-pip01-19 https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002594-pip02-20 EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book Human Metabolome Database (HMDB) http://www.hmdb.ca/citing http://www.hmdb.ca/metabolites/HMDB0247543 National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs https://www.cancer.gov/policies/copyright-reuse https://www.cancer.gov/about-cancer/treatment/drugs/infigratinibphosphate NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/2550729 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/07J RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=38052846-402819523 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=38052856-629277266 WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ Wikidata https://creativecommons.org/publicdomain/zero/1.0/ https://www.wikidata.org/wiki/Q27075200 https://pubchem.ncbi.nlm.nih.gov Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/mesh/67568950 http://www.nlm.nih.gov/mesh/meshhome.html https://www.ncbi.nlm.nih.gov/mesh/68000970 KEGG https://www.kegg.jp/kegg/legal.html http://www.genome.jp/kegg-bin/get_htext?br08303.keg http://www.genome.jp/kegg-bin/get_htext?br08310.keg http://www.genome.jp/kegg-bin/get_htext?br08330.keg NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 391729929 https://pubchem.ncbi.nlm.nih.gov/substance/391729929 h References
